Synthetic Biologics Inc., of Rockville, Md., reported preclinical data showing that SYN-005, a monoclonal antibody combination comprising hu1B7 and hu11E6, demonstrated prophylactic effect in a murine model of pertussis, with the antibodies, both individually and in combination, completely blocking the rise in white blood cell count that is characteristic of the disease and reduced bacterial colonization in the lungs.